Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B.

Ana Alvarez-CienfuegosLawrence H CheungKhalid A MohamedaliTimothy G WhitsettJeffrey A WinklesWalter N HittelmanMichael G Rosenblum

Published in: Journal for immunotherapy of cancer (2021)

GrB(C210A)-Fc-IT4 demonstrated excellent, specific cytotoxicity in vitro and impressive in vivo efficacy with no significant toxicity in normal murine models. These studies show GrB(C210A)-Fc-IT4 is an excellent candidate for further preclinical development.

Keyphrases

endothelial cells
oxidative stress
induced pluripotent stem cells
cancer therapy
pluripotent stem cells
cell therapy
binding protein
bone marrow
oxide nanoparticles